Tilrekimig for moderate-to-severe eczema in adults and teens
Tests tilrekimig against placebo in people with eczema alongside skin creams.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Key facts
- Where
- Bakersfield, Birmingham, Dallas, Fargo, Marietta, Miami, Northridge, Panama City, San Diego, Savannah, Scottsdale, Southlake, St. Petersburg, and West Hills, United StatesSee the 14 sites
- Phase
- Phase 3
Where in United States
- Kern Research, IncBakersfield, United StatesNot yet recruiting
- Cahaba Dermatology Skin Health CenterBirmingham, United StatesNot yet recruiting
- Derm TexasDallas, United StatesTaking people
- Red River Research Partners, LLCFargo, United StatesTaking people
- Marietta Dermatology Clinical Research, Inc.Marietta, United StatesTaking people
- Pediatric Skin ResearchMiami, United StatesTaking people
- Northridge Clinical TrialsNorthridge, United StatesTaking people
- AllerVie Clinical ResearchPanama City, United StatesTaking people
- University Clinical Trials, IncSan Diego, United StatesTaking people
- Aeroallergy Research Laboratories of Savannah, Inc.Savannah, United StatesNot yet recruiting
- Orso HealthScottsdale, United StatesNot yet recruiting
- Stryde Research-Epiphany DermatologySouthlake, United StatesNot yet recruiting
- GCP Research, Global Clinical professionalsSt. Petersburg, United StatesTaking people
- Focus Clinical ResearchWest Hills, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07765888EU 2026-526155-65-00
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated.Read full original descriptionShow less
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin condition that makes the skin dry, itchy, red, and irritated.
* This study is seeking participants who: Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD.
Participants in this study will randomly receive either tilrekimig or placebo at a 2:1 ratio. A placebo does not have any medicine in it but looks just like the medicine being studied. The study treatment period will be 24 weeks. The last dose of study treatment will be administered at week 20.
Some participants will join the long-term extension study C4531008 at week 24. A long-term extension study is an additional study that participants may be able to join after completing the main study. It allows researchers to continue collecting information about how well the study medicine works and how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last study treatment dose.
Inclusion: Participants 12 years of age or older; Must meet the following AD criteria:; Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1; An inadequate response to standard of care treatments {eg, at least medium potency topical corticosteroids (TCS)} consistent with AD treatment guidelines; Moderate-to-severe eczema for at least 1 year; Adolescent participants must be up to date on immunizations per local guidance.
Exclusion: Clinically Significant Autoimmune Disease; Significant Infection History or Active Infection; Significant psychiatric illness or suicidality; Known or Suspected Immunodeficiency/Immunosuppression; Clinically significant hepatic, renal, or hematologic abnormalities.